Biodistribution and antitumor effect of Cetuximab-targeted lentivirus

Nuclear Medicine and Biology

Volumn 41, Issue 1, 2014, Pages 77-83

  Huhtala, Tuulia ^a,b   Kaikkonen, Minna U ^a,c   Lesch, Hanna P ^a,c   Viitala, Sari ^a   Ylä Herttuala, Seppo ^a,d   Närvänen, Ale ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Biocenter Kuopio   (Finland)

^c Finland Ark Therapeutics Oy   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cetuximab; Gene therapy; Lentivirus; Ovarian carcinoma; SPECT CT; Targeting

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; BETA ACTIN; BETA INTERFERON; CETUXIMAB; IMC C 225; INDIUM 111; LENTIVIRUS VECTOR; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE TRANSFER; ISOTOPE LABELING; LIMIT OF DETECTION; MOUSE; NONHUMAN; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RADIOACTIVITY; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSGENE; TUMOR IMMUNITY; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

CETUXIMAB; GENE THERAPY; LENTIVIRUS; OVARIAN CARCINOMA; SPECT/CT; TARGETING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AVIDIN; BIOTINYLATION; CELL LINE, TUMOR; FEMALE; GENETIC VECTORS; HUMANS; INDIUM RADIOISOTOPES; LENTIVIRUS; MICE; OVARIAN NEOPLASMS; STREPTAVIDIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TRANSDUCTION, GENETIC;

EID: 84888319616     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.10.005     Document Type: Article

References (43)

1. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22:255-288.
2. Friedlander M.L. Prognostic factors in ovarian cancer. Semin Oncol 1998, 25:305-314.
3. Singh A.P., Senapati S., Ponnusamy M.P., Jain M., Lele S.M., Davis J.S., et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol 2008, 9:1076-1085.
4. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
5. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010, 28:2777-2783.
6. Phillips B.E., Giannoukakis N. Drug delivery technologies for autoimmune disease. Expert Opin Drug Deliv 2010, 7:1279-1289.
7. Chen H.X., Cleck J.N., Coelho R., Dancey J.E. Epidermal growth factor receptor inhibitors: current status and future directions. Curr Probl Cancer 2009, 33:245-294.
8. Secord A.A., Blessing J.A., Armstrong D.K., Rodgers W.H., Miner Z., Barnes M.N., et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008, 108:493-499.
9. Goldenberg D.M., Sharkey R.M., Paganelli G., Barbet J., Chatal J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006, 24:823-834.
10. Aiuti A., Roncarolo M.G. Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 2009, 682-689.
11. Nanou A., Azzouz M. Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 2009, 175:187-200.
12. Schambach A., Baum C. Clinical application of lentiviral vectors-concepts and practice. Curr Gene Ther 2008, 8:474-482.
13. Gray S.J., Samulski R.J. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008, 8:911-922.
14. Ferrer E. Trabecular meshwork as a new target for the treatment of glaucoma. Drug News Perspect 2006, 19:151-158.
15. Lundstrom K. Gene therapy applications of viral vectors. Technol Cancer Res Treat 2004, 3:467-477.
16. Wu T.L., Ertl H.C. Immune barriers to successful gene therapy. Trends Mol Med 2009, 15:32-39.
17. Sinn P.L., Sauter S.L., McCray P.B. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther 2005, 12:1089-1098.
18. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
19. Kafri T., Blomer U., Peterson D.A., Gage F.H., Verma I.M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997, 17:314-317.
20. Kaikkonen M.U., Lesch H.P., Pikkarainen J., Raty J.K., Vuorio T., Huhtala T., et al. (Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery. Gene Ther 2009, 16:894-904.
21. Lesch H.P., Turpeinen S., Niskanen E.A., Mahonen A.J., Airenne K.J., Yla-Herttuala S. Generation of lentivirus vectors using recombinant baculoviruses. Gene Ther 2008, 15:1280-1286.
22. Raty J.K., Liimatainen T., Huhtala T., Kaikkonen M.U., Airenne K.J., Hakumaki J.M., et al. SPECT/CT imaging of baculovirus biodistribution in rat. Gene Ther 2007, 14:930-938.
23. Sallinen H., Anttila M., Narvainen J., Orden M.R., Ropponen K., Kosma V.M., et al. A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol Oncol 2006, 103:315-320.
24. Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, Sehouli J, et al. An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer 2011;11:294,2407-11-294.
25. 111In-labeled monoclonal antibodies. Nucl Med Biol 2010, 37:957-964.
26. Brown B.D., Sitia G., Annoni A., Hauben E., Sergi L.S., Zingale A., et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 2007, 109:2797-2805.
27. Kenworthy R., Lambert D., Yang F., Wang N., Chen Z., Zhu H., et al. Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Res 2009, 37:6587-6599.
28. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.
29. Hovanessian A.G., Brown R.E., Kerr I.M. Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature 1977, 268:537-540.
30. Kerr I.M., Brown R.E. pp pA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci U S A 1978, 75:256-260.
31. Arwert E., Hingtgen S., Figueiredo J.L., Bergquist H., Mahmood U., Weissleder R., et al. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res 2007, 67:7335-7342.
32. Miletic H., Fischer Y.H., Giroglou T., Rueger M.A., Winkeler A., Li H., et al. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res 2007, 13:6761-6768.
33. Sumimoto H., Kawakami Y. Lentiviral vector-mediated RNAi and its use for cancer research. Future Oncol 2007, 3:655-664.
34. Hu B., Tai A., Wang P. Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 2011, 239:45-61.
35. Schauber C.A., Tuerk M.J., Pacheco C.D., Escarpe P.A., Veres G. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro. Gene Ther 2004, 11:266-275.
36. Banerjee D., Matthews P., Matayeva E., Kaufman J.L., Steinman R.M., Dhodapkar K.M. Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcgammaRs on human dendritic cells. J Immunother 2008, 31:113-120.
37. Kim E.J., Lee J.M., Namkoong S.E., Um S.J., Park J.S. Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells. J Cell Biochem 2002, 85:369-380.
38. Beignon A.S., McKenna K., Skoberne M., Manches O., DaSilva I., Kavanagh D.G., et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005, 115:3265-3275.
39. Fonteneau J.F., Larsson M., Beignon A.S., McKenna K., Dasilva I., Amara A., et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 2004, 78:5223-5232.
40. Kalinski P., Giermasz A., Nakamura Y., Basse P., Storkus W.J., Kirkwood J.M., et al. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 2005, 42:535-539.
41. Dao T., Gomez-Nunez M., Antczak C., Kappel B., Jaggi J.S., Korontsvit T., et al. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell-associated antigens. Clin Cancer Res 2005, 11:8763-8772.
42. Hoffmann T.K., Meidenbauer N., Dworacki G., Kanaya H., Whiteside T.L. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000, 60:3542-3549.
43. Jenne L., Arrighi J.F., Jonuleit H., Saurat J.H., Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res 2000, 60:4446-4452.